Alnylam Pharmaceuticals (NASDAQ:ALNY) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Reflections on Alnylam | Nature Biotechnology
Alnylam Issues 2022 Corporate Responsibility Report
Alnylam Pharmaceuticals on X: "Today, we are delighted to announce that the European Commission (@EMA_news) approved our #RNAi therapeutic for the treatment of #hATTR #amyloidosis with stage 1 or 2 polyneuropathy, an
Press Release
Alnylam grabs FDA approval for its second amyloidosis therapy | pharmaphorum
Alnylam Pharmaceuticals and GENESIS Pharma partner to commercialize patisiran in South East Europe
Alnylam Announces 2018 Corporate Goals | Business Wire
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis | ALNY Stock News
Paul Nioi on LinkedIn: Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal…
Alnylam annonce un partenariat avec Roche pour co-développer et co-commercialiser le zilebesiran, une thérapie iARN expérimentale pour le traitement de l'hypertension chez les patients à haut risque cardiovasculaire | Business Wire
Alnylam® Newsroom
Bill Bodin on LinkedIn: Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi…
Alnylam Pharmaceuticals on X: "Today we shared new results from the ongoing Phase 1 study of ALN-HSD, an investigational #RNAi therapeutic targeting HSD17B13 in nonalcoholic steatohepatitis (NASH) patients and healthy volunteers, in
Press Releases | Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals on LinkedIn: Alnylam Announces Updates to its Board of Directors
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults | Business Wire
Alnylam Pharmaceuticals Press Release | Feb 02, 2024
Alnylam® Pharmaceuticals Media Kit
We evaluated zilebesiran, our RNAi therapeutic for hypertension. | Alnylam Pharmaceuticals posted on the topic | LinkedIn
Harnessing Human Genetics to Power the Next Wave of RNAi Therapeutics | Alnylam® Newsroom
Dr. Yvonne Greenstreet on LinkedIn: Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy…
Articles about Alnylam Pharmaceuticals
Alnylam announces positive results for Alzheimer's treatment
Alnylam Pharmaceuticals on LinkedIn: Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi…
Alnylam to face FDA Adcomm for Onpattro's ATTR-CM bid
